Synaptogenix Receives Notice of Allowance for U.S. Patent Application: A Step Forward in the Treatment of Neurodegenerative Diseases.

Synaptogenix, Inc. (NASDAQ: SNPX) has recently made headlines with its significant achievement in the field of neurodegenerative disease treatment. The pioneering biopharmaceutical company has received a Notice of Allowance for its U.S. Patent Application 17/665,033 titled "Halogenated Esters of Cyclopropanated Unsaturated Fatty Acids for Use in the Treatment of Neurodegenerative Diseases". $Synaptogenix (SNPX.US)$